Schoecklmann H O, Rupprecht H D, Zauner I, Sterzel R B
Medizinische Klinik IV, Universität Erlangen-Nürnberg, Germany.
Kidney Int. 1997 Apr;51(4):1228-36. doi: 10.1038/ki.1997.168.
In glomerular disease, transforming growth factor-beta1 (TGF-beta1) has been demonstrated to exert anti-mitogenic and anti-inflammatory as well as fibrogenic effects. To better understand the TGF-beta1 action on glomerular cells at the molecular level, we investigated mechanisms of TGF-beta1-induced growth suppression in primary cultures of rat mesangial cells (MCs). TGF-beta1 (5 ng/ml) markedly inhibited proliferation of MCs incubated with PDGF, endothelin-1, bFGF, serotonin, or EGF, indicating that TGF-beta1 interferes with post-receptor signals of mitogenesis. TGF-beta1 did not affect mitogen-stimulated induction of the immediate early genes, c-fos, c-jun, and Egr-1 in MCs that occurred transiently at 30 to 120 minutes. Time-course studies revealed that TGF-beta1 inhibited DNA synthesis and MC replication when added up to six to eight hours after MC stimulation with PDGF. FACS analysis demonstrated that MCs had reached middle to late G1 phase of cell cycle progression at this timepoint. PDGF stimulation of MCs induced protein expression of the G1 phase cyclin D1 as well as the cyclin-dependent kinases cdk 4 and cdk 2. This was not significantly altered when MCs were coincubated with both, PDGF and TGF-beta1. However, TGF-beta1 prevented PDGF-elicited phosphorylation of the retinoblastoma tumor suppressor (pRb), a negative cell cycle regulator. Moreover, TGF-beta1 significantly reduced cyclin E-associated histone H1 kinase activity in the presence of PDGF. These results indicate that TGF-beta1 inhibits mitogen-stimulated MC growth by causing cell cycle arrest in late G1 phase. While TGF-beta1 does not alter the mitogen-induced expression and abundance of G1 phase cyclin D1 and cdks 4 and 2 in MCs, it inhibits cyclin E-cdk 2 activity, thus preventing mitogen-elicited phosphorylation and inactivation of pRb in G1 phase and transition to S phase.
在肾小球疾病中,已证实转化生长因子-β1(TGF-β1)具有抗有丝分裂、抗炎以及促纤维化作用。为了在分子水平上更好地理解TGF-β1对肾小球细胞的作用,我们研究了TGF-β1诱导大鼠系膜细胞(MCs)原代培养物生长抑制的机制。TGF-β1(5 ng/ml)显著抑制与血小板衍生生长因子(PDGF)、内皮素-1、碱性成纤维细胞生长因子(bFGF)、5-羟色胺或表皮生长因子(EGF)共同孵育的MCs的增殖,表明TGF-β1干扰有丝分裂的受体后信号。TGF-β1不影响有丝分裂原刺激的MCs中即时早期基因c-fos、c-jun和早期生长反应基因-1(Egr-1)的诱导,这些基因在30至120分钟时短暂出现。时间进程研究表明,在用PDGF刺激MCs后6至8小时内添加TGF-β1可抑制DNA合成和MCs复制。流式细胞术分析表明,此时MCs已进入细胞周期进程的G1期中期至后期。PDGF刺激MCs可诱导G1期细胞周期蛋白D1以及细胞周期蛋白依赖性激酶cdk 4和cdk 2的蛋白表达。当MCs与PDGF和TGF-β1共同孵育时,这种情况没有明显改变。然而,TGF-β1可阻止PDGF诱导的视网膜母细胞瘤肿瘤抑制因子(pRb)的磷酸化,pRb是一种负性细胞周期调节因子。此外,在存在PDGF的情况下,TGF-β1显著降低细胞周期蛋白E相关的组蛋白H1激酶活性。这些结果表明,TGF-β1通过使细胞周期停滞在G1期后期来抑制有丝分裂原刺激的MCs生长。虽然TGF-β1不会改变有丝分裂原诱导的MCs中G1期细胞周期蛋白D1以及cdk 4和2的表达和丰度,但它会抑制细胞周期蛋白E-cdk 2活性,从而阻止有丝分裂原诱导的G1期pRb磷酸化和失活以及向S期的转变。